SOPH

Business Context and Reporting Period

SOPHiA GENETICS SA (Nasdaq: SOPH) is a Swiss cloud-native software company providing the SOPHiA DDM Platform for data-driven medicine. The platform analyzes complex multimodal datasets (genomics, radiomics, clinical data) to generate insights for oncology, rare diseases, and biopharma applications. This summary covers the fiscal year ended December 31, 2024, as reported in the Form 20-F.

Key Financial Metrics

Key Performance Indicators:

• Platform Analysis Volume: 352,628 (up 11% from 2023).
• Core Genomics Customers: 472 (up from 450 in 2023).
• Net Dollar Retention (NDR): 104% (down from 130% in 2023).

Material Changes vs. Prior Period

• Revenue Growth: Driven by a 11% increase in platform analysis volume, particularly in Oncology (HemOnc) and Rare Disorders applications. Growth was partially offset by a $1.9 million decrease in biopharma revenue and a $0.1 million foreign exchange headwind.
• Cost of Revenue: Increased by 9% to $21.2 million, primarily due to a $1.4 million increase in amortization of capitalized software development costs and higher material costs. This contributed to a slight compression in gross margin.
• Operating Expenses: Total operating expenses decreased by 6% to $110.5 million.
  • R&D: Decreased 7% to $34.4 million due to reduced professional fees and cost-saving efforts.
  • G&A: Decreased 12% to $47.0 million, driven by headcount reductions and lower executive bonuses.
  • S&M: Increased 3% to $29.4 million due to higher marketing and conference expenses.
• Non-Operating Items:
  • Foreign Exchange: Shifted from a $7.6 million loss in 2023 to a $3.5 million gain in 2024, largely due to unrealized gains on intercompany receivables.
  • Interest Expense: Increased to $1.9 million from $0.6 million due to the new Perceptive Credit Agreement.

Guidance, Outlook, and Risks

Outlook and Strategy: The company expects to continue incurring net losses as it invests in R&D for multimodal data analytics, expands sales in under-penetrated regions (North America, APAC), and pursues regulatory clearances for In Vitro Diagnostic (IVD) products. Management believes existing cash ($80.2 million) is sufficient for at least the next 12 months.

Material Risks and Contingencies:

• Regulatory Uncertainty: The FDA's May 2024 final rule on Laboratory Developed Tests (LDTs) may increase costs and reduce demand for RUO products. The company is transitioning toward IVD status but faces uncertainty regarding approval timelines.
• Debt Covenants: The Perceptive Credit Agreement includes a revenue covenant requiring $51.8 million in trailing twelve-month revenue (tested quarterly) and a minimum cash balance of $3.0 million. The company was in compliance as of December 31, 2024.
• Cloud Commitments: The company has a minimum purchase commitment of approximately $58.8 million remaining with Microsoft Azure through 2028.
• Profitability: The company has an accumulated deficit of $440.3 million and may never achieve or sustain profitability.

Investor Verification Checklist

• Debt Compliance: Verify continued compliance with the Perceptive Credit Agreement revenue covenant ($51.8M LTM) and cash covenants in upcoming quarters.
• Regulatory Path: Monitor progress on FDA 510(k) or PMA submissions for IVD products and the impact of the new LDT rule on RUO revenue streams.
• Cash Burn: Assess the sustainability of the ~$58 million annual cash burn rate against the $80.2 million cash balance and the $35 million undrawn credit facility.
• Customer Concentration: Note that one distributor accounted for $8.2 million (approx. 12.6%) of 2024 revenue; monitor for concentration risks.
• Cloud Costs: Evaluate the impact of the $58.8 million remaining Microsoft Azure commitment on future gross margins.